Salary

Wow. Super helpful.

 

A Ford Taurus CLI

 

We all know people who left for raises of $40,000-$60,000 in salary, better stock plans and new product launches. The naysayers here said they’d regret it. So far none of them have. The positions are out there. So why do we stay?

 

Plenty that have left regret it - some of them have been at 2-3 companies since they left- no thanks !

 

It’s definitely not the max for GI. I doubt that they would pay 90 for PCP.

 

Liar. A few got burned by Intercept. The people who went to BMS, Regeneron and Sanofi are happy and making bank. And they are selling amazing products that physicians are interested in. Xifaxan is a one trick pony. Our leadership sucks and has no plan. No new products coming based on the NSM. Salix sucks and you know it. You’re just jealous you didn’t get out when BMS and the others came knocking.

 

Truth

 

You must not have been here very long. I’m talking way past the last rounds of companies. Sure there are some that are happy, but there are also plenty that regret leaving. A sure thing does not exist, and a multi Billion dollar “one trick pony” as you call it like Xifaxan can go a long way. (And plenty of physicians are interested in it)

 

Xifaxan prescriptions are growing by single digit percentage. Been that way a long time. Most of our growth has been price increases. The old Valeant model is alive and well. HE price is about $4,600 a month. IBSD is $2,400 for two weeks. And before you try to “educate” me on the copay card and how “nobody pays out of pocket for Xifaxan,” STFU. Insurance providers, Medicaid and Medicare are paying for it which means we all pay either through our taxes or higher insurance premiums. The brand is not growing organically. Admit it.

You cannot compare Xifaxan to a mega billion biologic like Dupixent. There are major announcements and news stories about Dupixent every week. They just got the first line indication for EoE which no other drug has. When was the last time we saw a major news or industry announcement about Xifaxan? Try comparing our stock price to Regeneron. BHC market cap is now $3.4BB at $9.67 a share. Regeneron has $67.0BB market cap at $624.65 per share.

This company has been a shit show since 2016. How many people can you name who tried to get into Salix after leaving? Zero.

 

Truth

 

The statement above is all true. JC and his minions will squeeze every last drop out of Xifaxan. They will bankrupt Salix and take their massive bonus and stock payouts and move on to their next host like the parasites they are. In the meantime, we, the field sales people who actually deliver value to the bottom line, will be summarily kicked to the curb with two weeks severance and no benefits. Tell me I’m wrong a year from now.

The saddest part about this whole scenario is that Xifaxan is an incredible product. If it stayed with Salix and Valeant never got their filthy hands on it, we’d probably have a couple more indications and double the number of prescriptions.

 

Dupixent and regeneron are great. The EOE indication, for the GI salesforce isn’t that appealing. They will be begging for patients in 6 months

 

Well then they can lean on the Dupixent deem team for additional revenue. Because they just got ANOTHER new indication today for atopic dermatitis.

Any new announcements for Xifaxan lately?